Background {#Sec1}
==========

In the past decade, intensity modulated radiotherapy (IMRT) and volumetric modulated radiotherapy (VMAT) became standard techniques for external beam radiotherapy treatments (EBRT) of many indications. The inverse optimization approach is an iterative process where optimization objectives are used in order to achieve the pre-defined clinical goals. Additionally, help structures are frequently defined to shape the dose distribution and further individualize and optimize the treatment plan. The complexity of the optimization increases with the number of organ at risks (OAR) and the number of target volumes. Head and neck carcinoma (HNC) is a typical complex case where a large number of OARs, typically 10--20, are surrounding the target volumes irradiated to different dose levels. This makes inverse planning optimization one of the most time consuming steps of the overall treatment planning process.

Additionally, plan quality may vary between planners and between clinical institutions. Plans produced by an experienced center may outperform those produced in a less experienced center \[[@CR1]\] and the OAR sparing also depends on the planning target volume (PTV) dose homogeneity requirements \[[@CR2]\]. Furthermore, evaluation of plan quality is often based on population-based dose volume histogram parameters (DVH), which neglect the nuances of an individual patients' geometry and therefore do not achieve the optimal solution based on a patient-individual level \[[@CR3]\]. In order to overcome these issues, optimization modules were developed in order to automate part or the entire optimization \[[@CR4]--[@CR9]\] process. They all aim at reducing the inter-planner variability, reducing the planning time allocated for the optimization process and finally improving the overall plan quality \[[@CR10], [@CR11]\]. Nowadays, automated treatment planning and/or optimization systems (ATPS) are in the process of broad clinical implementation. However, since ATPS have to be customized in order to fulfill the specific constraints required by different medical centers, it could be that an ATPS implemented at one institution will not necessary work for patients from another institution. The goal of this study was to compare different ATPS for HNC planning in a multicenter setting.

Additionally, it was evaluated if a model for automated planning developed by one institution could be used for planning cases of another institution using similar but not the same structures and planning goals. This multi-institutional planning comparison of five ATPS solutions is, to the best of our knowledge, the first of its kind.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

In this multi-institutional planning study, five automated treatment planning systems used in 3 different institutes were evaluated:Automatic Interactive Optimizer (AIO) (in-house developed) in combination with RapidArc version 13.7 from Eclipse (Varian Medical Systems, Palo Alto, USA) from hospital B \[[@CR4], [@CR12]\];Auto-Planning version 14.0 (AP) from Pinnacle (Philips Radiation Oncology Systems) from hospital A \[[@CR6]\];RapidPlan version 13.6 (RP1) from Eclipse (Varian Medical Systems, Palo Alto, USA) using HNC model from hospital A;RapidPlan version 13.7 (RP2) combined with scripting for automated setup of fields with HNC model from hospital B \[[@CR13]\];Raystation multicriteria optimization algorithm version 5 (RS) (RaySearch Laboratories AB, Stockholm, Sweden), from hospital C.

Ten randomly selected locally advanced HNC cases were chosen from each of two different institutes (A and B). Two cases from each group were used to familiarize with the target volume, concepts, dose constraints and to generate an automated planning strategy. A single optimization using the same strategy was performed for the remaining cases. Only these eight cases for each institution, overall 16 cases, were included in the planning comparison.

Patients from institute A had three PTV dose levels, with doses of 70 Gy, 60 Gy and 54 Gy planned in 35 fractions using a simultaneous integrated boost (SIB), see Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. The dose was normalized to PTV 70Gy mean dose = 70 Gy.Table 1Targets, organs at risk and objectives used for plan optimizationInstitution AInstitution BPrescription 70 Gy, 60 Gy and 54 Gy70 Gy and 54 Gy  35 fractions with a simultaneous integrated boostBeam arrangement 2 volumetric modulated arcs, 6MV photonsPTVs PTV 70Gy Dmean = 70GyPTV 70Gy D95% = 98% PTV 70Gy V95% \> 95%PTV 70Gy V107% \< 5% PTV 70Gy D2% \> 75GyPTV 54Gy D95% \> 98% PTV 60Gy V95% \> 95%PTV 54Gy V107% \< 5% PTV 54Gy V95% \> 95%Serial organs Brainstem Dmax \< 54 GyBrainstem + 3 mm Dmax \< 50 Gy Brachial Plexus D0.5cm^3^ \< 60 Gy Mandible V70 Gy \<  1 cm^3^Mandible Dmax \< 70 Gy Spinal cord \< 45 GySpinal cord + 3 mm Dmax \< 54 GyParallel organsUATCricopharyngeal GlottisLarynx LowerLarynx Upper Pharynx constrictorSuperior PCMMedial PCMInferior PCM Upper esophagusUpper esophagusUpper Esophageal Sphincter ThyroidThyroid TracheaTrachea Oral cavityOral cavity ParotidsParotids Submandibular glandsSubmandibular glands*Abbreviation*: *PCM* pharyngeal constrictor muscles, *UAT* upper aerodigestve tractFig. 1Example of one head and neck case from institution A (**a**) and one from institution B (**b**). In red, blue and light green the PTVs 70 Gy, 60 Gy and 54 Gy respectively as well as the OARs

Patients from institute B had two dose levels defined: 70 Gy and 54 Gy in 35 fractions using a SIB, see Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. The dose was normalized such that 95% of the PTV 70 Gy volume received 98% of the prescribed dose (70 Gy).

For both sets of patients, hard planning constraints were set for the PTVs and serial OAR, which had to be fulfilled by all planning system and patient cases, see Table [1](#Tab1){ref-type="table"}. For the parallel OARs, the mean dose was asked to be kept as low as reasonably achievable. All plans were optimized with a 2 arc, 6 MV VMAT technique.

Plan evaluation {#Sec4}
---------------

Dose-volume histogram (DVH) parameters were calculated for the PTVs and each of the OARs listed in Table [1](#Tab1){ref-type="table"}. Maximum doses for the serial OAR were reported but the differences were not considered in this planning comparison. This allows the optimization algorithm to further reduce dose to the parallel organs. The dose bath was evaluated based on the volumes covered by the 50 Gy, 30 Gy and 5 Gy isodose surfaces.

Doses to parallel OARs were evaluated based on their mean dose. A ranking for each parallel OAR was performed per patient. A rank of 1 was given for the ATPS achieving the lowest mean dose for a given OAR. Each ATPS achieving a dose within 3 Gy to the lowest achieved dose was given a ranking of 1, assuming that a dose difference \< 3 Gy was not clinically relevant in our case \[[@CR14]--[@CR16]\]. The ATPS achieving a dose within 3 Gy -- 6 Gy to the lowest achieved dose had a rank of 2, within 6 Gy -- 9 Gy, a rank of 3, etc. The mean ranking was calculated for the individual swallowing muscles plus trachea and thyroid gland resulting in a structure called upper aerodigestive tract (UAT).

Finally, an overall mean ranking was taken by averaging the mean rank for parotid glands, submandibular glands and oral cavity.

The time required to generate a plan was evaluated and divided into 2 parts:The effective working time was defined as the time required by the planner to generate a plan. This included the time needed for the definition of auxiliary structures and definition of bolus structures if a PTV reached the skin surface. For RS, it also included the user navigation through the Pareto-optimal plan database. This time didn't include the time required for the optimization.Optimization time, during which no interaction of the user was needed. For RS, it includes the automatic generation of Pareto-optimal plans and the final deliverable plan.

Automated treatment planning system {#Sec5}
-----------------------------------

### AIO {#Sec6}

Using the application programming interface (API) of the Eclipse treatment planning system, several scripts were developed to; create the PTV structures used in the optimization; generate ring structures around the PTVs; position two RapidArc fields and the isocenter positioned in the center-of-mass of the total PTV. The scripts automatically positioned fixed optimization objectives for the PTVs, serial OARs, and ring structures, while for each parallel OAR, 10 optimization objectives are positioned evenly spread among the volume axis. After this, the user has to manually open the optimization window of the treatment planning system to start the automatic interactive optimization (AIO) process. AIO is a program that automatically adapts the optimization objectives of the parallel OAR during the optimization process, keeping them at a fixed distance from the DVH-line at all times \[[@CR12], [@CR17]\].

### Auto-planning {#Sec7}

Auto-Planning (AP), included in Pinnacle 14.0 (Philips Radiation Oncology Systems), is a fully integrated module in the TPS, similar to the "manual" inverse optimizer module and has been previously described \[[@CR6], [@CR18]\]. Briefly, Pinnacle AP is a template-knowledge based treatment planning system. During AP, a plan is automatically loaded and the isocenter placed at the center-of-mass of the total PTV. The optimizer is than automatically run multiple times with the individual optimization goals, constraints and weights automatically added and adjusts the priority of clinical goals based on their probability of being achieved.

### RapidPlan with a model from institute A (RP1) {#Sec8}

Rapidplan (RP) is a knowledge-based automatic planning solution. A set of previously created plans representative of the internal hospital guidelines are fed into the program, which through a statistical modeling, creates a model. This model takes into account the geometrical and dosimetrical properties of the plans and is able to generate individualized constraints for the future plans taking into account their particular geometry, based on the library plans. Since RP is based on hospital-specific plans, the model is optimized to produce plans with a specific dose distribution and to accept OAR within a certain size and location. RP1 model was based on 83 clinically delivered HNC plans with SIB concept but variable dose levels created using 6MV photons and 2 full arcs. Since OAR definition from Institution A was different from Institution B, it was necessary to sum several OARs from Institution B before RP1 could be used.

### RapidPlan with a model from institute B (RP2) {#Sec9}

The same script as for AIO was used for the creation of the RapidPlan plans. However, instead of positioning all optimization objectives as a preparation for AIO, a script was developed to call a RapidPlan model from institute B to predict achievable OAR doses and position optimization objectives for the various targets and OARs. This model was based on 177 clinical patient plans, which is an extension of a previously made model \[[@CR13]\].

### Raystation {#Sec10}

The MultiCriteria optimization algorithm MCO is a convex optimization problem \[[@CR19]\] based on the approximation of the Pareto surface-based technique \[[@CR20]\] where a set of Pareto-optimal plans is automatically generated and stored in a database for each patient. The user can navigate through this "Pareto-optimal" plans database and assess in real-time the tradeoff between different objective functions assigned to each anatomical structure. The desired plan that meets the clinical goals is then selected by the planner and generated to be delivered to the patient \[[@CR21]\]. In this study, the geometry of planning targets volumes PTVs were replaced with convex approximation geometry in order to fully benefit from the MCO technique. The DVH-based functions were used as hard constraints in order to respect the clinical constraints.

Statistical analysis {#Sec11}
--------------------

The mean dose to the parallel organs were reported as well as the standard deviation. The Wilcoxon signed rank test was used to compare the mean doses of the parallel organs of each planning system with those of the planning system that achieved the lowest mean dose. A *p* ≤ 0.05 was considered significant.

Results {#Sec12}
=======

Dose distribution {#Sec13}
-----------------

The detailed results for the five ATPS are included in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Each planning system were able to be modified successfully to achieve the hard constraints for the PTVs and serial organs for each patients listed in Table [1](#Tab1){ref-type="table"}. Small variations in serial OAR doses were observed between the different ATPS but were judged as clinically irrelevant.Table 2Detailed results for the PTVs, dose bath and serial organsStructureAIOAPRP1RP2RSMeanSDMeanSDMeanSDMeanSDMeanSDTargetsPTV 70GyDmean (Gy)70.90.270.50.370.80.370.50.370.40.2V95% (%)97.60.698.90.297.70.697.80.598.80.2D2% (Gy)73.40.472.60.273.60.273.30.172.10.1PTV60GyV95% (%)98.90.499.90.199.10.399.00.299.70.2PTV 54GyV95% (%)98.20.498.70.698.30.498.80.398.00.6Dose bathBodyV50Gy (dm^3^)1.020.341.120.340.960.301.000.320.940.32V30Gy (dm^3^)2.500.622.320.662.120.562.380.611.880.43V5Gy (dm^3^)6.391.287.121.406.831.356.541.406.641.36Serial OrgansBrachial PlexusD0.5 cm^3^ (Gy)53.13.553.14.354.23.652.72.751.17.4BrainstemDmax (Gy)30.215.527.413.626.214.730.612.823.713.4MandibleDmax (Gy)67.84.666.65.568.07.967.112.067.03.2Spinal cordDmax (Gy)40.70.841.52.241.32.140.81.336.02.9*Abbreviations*: *AIO* automatic Interactive Optimizer, *AP* auto-planning, *RP* RapidPlan, *RS* Raystation, *V* ~*95%*~ percentage volume receiving 95% of prescribed dose, *D* ~*2%*~ dose corresponding to 2%, *D* ~*0.5\ cm*~^*3*^ dose corresponding to 0.5 cm^3^, *V* ~*X\ Gy*~ volume receiving X Gy, *Dmax* maximal dose, *SD* standard deviationTable 3Detailed results for the parallel organs. Statistical significance was tested for each parallel organ group in comparison with the planning system that achieved lowest averaged mean dose (bold). Any 0.01 ≤ *p* ≤ 0.05 is indicated with a \*, and *p* ≤ 0.01 is indicated with \*\*AIOAPRP1RP2RSMean ± SDRank± SDMean ± SDRank ±SDMean ± SDRank ±SDMean ± SDRank ±SDMean ± SDRank ±SD(Gy)(Gy)(Gy)(Gy)(Gy)OralCavity36.1 ± 16.8 \*\*2.56 ± 1.2133.8 ± 17.8\*1.63 ± 0.6234.1 ± 16.7\*\*1.81 ± 0.7536.3 ± 16.2\*\*2.75 ± 1.34**31.3 ± 17.6**1.06 0.25Parotid21.9 ± 6.31.31 ± 0.6**21.2 ± 5.9**1.19 ± 0.4021.6 ± 6.31.25 ± 0.4522.8 ± 6.21.50 ± 0.7321.4 ± 6.21.19 ± 0.54Submand. Glands35.2 ± 8.41.94 ± 1.34**33.6 ± 10.8**1.44 ± 0.8138.2 ± 7.0 \*\*2.88 ± 1.4135.5 ± 9.31.88 ± 1.0936.9 ± 7.6\*2.38 ± 1.15UAT**38.8 ± 9.3**1.49 ± 0.3739.3 ± 9.41.86 ± 0.6443.4 ± 7.6\*\*2.99 ± 1.0139.7 ± 8.91.89 ± 0.740.4 ± 8.42.00 ± 0.70Average1.83 ± 1.06\***1.53 ± 0.67**2.23 ± 1.20\*\*2.00 ± 1.08\*1.66 ± 0.91*Abbreviations*: *AIO* automatic interactive optimizer, *AP* auto-planning, *RP* RapidPlan, *RS* Raystation, *SD* standard deviation, *UAT* upper aerodigestve tract

The dose bath V~50\ Gy~ and V~30\ Gy~ was lowest for RS~,~ whereas AIO had the lowest V~5\ Gy~, see Table [2](#Tab2){ref-type="table"}. AP had on average the largest volume exposed to 50 Gy and 5 Gy. V~50\ Gy~ and V~30\ Gy~ were increased in comparison to RS by 1.9 ± 10.6% and 12.9 ± 18.0% (RP1), 6.1 ± 10.4% and 27.0 ± 13.7% (RP2), 8.7 ± 12.4% and 33.2 ± 13.0% (AIO), 18.5 ± 17.6% and 23.9 ± 17.8% (AP). V~5\ Gy~ was increased in comparison to AIO by 2.4 ± 3.7% (RP2), 3.9 ± 4.7% (RS), 6.8 ± 9.9% (RP1) and 11.4 ± 12.8% (AP).

The mean dose results for the parallel organs are summarized in Table [3](#Tab3){ref-type="table"}. Overall, AP had the best overall ranking for the parallel organs followed by RS (*p* = 0.20), AIO (*p* = 0.03), RP2 (*p* = 0.01), and RP1 (*p* \< 0.01). When looking at each organ separately, the oral cavity mean dose was significantly lower with RS (31.3 ± 17.6 Gy) compared to AP (33.8 ± 17.8 Gy), RP1 (34.1 ± 16.7 Gy), AIO (36.1 ± 16.8 Gy) and RP2 (36.3 ± 16.2 Gy), *p* \< 0.05. The lowest, respectively the highest, parotids mean dose was 21.2 ± 5.9 Gy (AP) and 22.8 ± 6.2 Gy (RP2) respectively. No significant differences were observed between the ATPS (*p* \> 0.2). The submandibular glands mean dose was 33.6 ± 10.8 Gy (AP), 35.2 ± 8.4 Gy (AIO), 35.5 ± 9.3 Gy (RP2), 36.9 ± 7.6 Gy (RS) and 38.2 ± 7.0 Gy (RP1). Only RP1 and RS were significantly different to AP. In the subgroup of the UAT, large dose variations, up to 15 Gy, were observed for small structures such as the cricopharynx or the upper pharyngeal constrictor muscles between the ATPS. Averaging over all UAT structures reduced the differences. The lowest UAT mean dose was obtained with AIO (38.8 ± 9.3 Gy), AP (39.3 ± 9.4 Gy), RP2 (39.7 ± 8.9 Gy), RS (40.4 ± 8.4 Gy) and RP1 (43.4 ± 7.6 Gy). RP1 was the only ATPS having a significantly higher mean UAT dose compared to the ATPS achieving the lowest mean dose (AIO), *p* \< 0.01.

Planning time {#Sec14}
-------------

The effective working time required after volume definition by the clinicians to the end of the optimization process was evaluated for every planning system. This time was kept below 2 min for each plan optimized with AIO and RP 2, see Table [4](#Tab4){ref-type="table"}. The mean effective working time was increased by 3 ± 1 for AP, 13 ± 2 by RP1 and 116 ± 11 min by RS, respectively.Table 4Effective working time and optimization timeAIOAPRP1RP2RSMeanStDevMeanStDevMeanStDevMeanStDevMeanStDevEff. working time (min)\<  2\<  151152\<  1\< 111611Optimization time (min)314831027428721830*Abbreviations*: *AIO* automatic interactive optimizer, *AP* auto-planning, *RP* RapidPlan, *RS* Raystation

Discussion {#Sec15}
==========

This study presented a multi-institutional planning comparison study of five ATPS used in 3 different institutes, performed on 16 locally advanced head and neck cancer patients coming from two institutes. Although larger differences were observed for an individual patient, when looking at the mean results over all 16 patients, dosimetric differences between ATPS were generally small with Auto-Planning achieving the best ranking. Effective working time differed considerably more between ATPS, from 2 up till 116 minutes.

ATPS can be classified between automated optimization and automated planning, including optimization. The automated optimization can again be distinguished as optimization algorithm driven systems, such as AIO, AP and RS, were the objectives and/or priorities are automatically adjusted during the optimization and knowledge based planning systems based on plan libraries such as RP1 and RP2. The automated optimization algorithm driven systems can be easily modified to take into account possible changes in clinical protocols. This is not necessary the case for the knowledge based planning systems which rely on plans for a database of prior patients. Contrariwise, the use of a database allows a comparison between the predicted and achieved dose volume histogram \[[@CR13]\].

The second classification can be performed based on automated planning where not only the optimization process is automated but also the field setup, gantry and collimator angles, the positioning of the isocenter and help structures such as bolus, rings structures or non-overlapping structures. This fully automated process was used by AIO, AP and RP2. RP1 and RS could also automate these planning process but it was not implemented.

After dose optimization, a single plan was generated by each ATPS except for RS where the user had to select a plan from a database of Pareto-optimal plans. This manual step will reduce the inter-planner standardization but will allow the user to choose the best dose trade-off between the targets and OARs.

Wu et al. \[[@CR22]\] compared AP and RP, for oropharyngeal cancer patients and found that the plan quality from both systems was comparable. Differences between the two systems were in the range of 5%, which is in good agreement to the small differences observed in our study. To the best of our knowledge, no other ATPS comparisons are available.

The two sets of HNC were chosen to evaluate the flexibility of the different ATPS to take into account new structures, objectives and/or different dose levels. The model for AIO, AP and RS could be easily modified because they are based on a set of user pre-defined DVHs parameters, which were automatically adjusted during the optimization. However for the RS, the combination of objectives/constraints and the selection of their formulation had to be adjusted manually for each plan depending on the overlap between the PTV and OAR which affects directly the Pareto surface computation. This is not the case for RP models, which are based on previously generated site-specific plan libraries. In this case, the model had to be manually modified to take into account the structures not defined in the library. RP1 and RP2 were both used without considering whether a particular structure was an outlier. At later inspection, all OAR of the third case from group A were listed as "outside threshold values" for RP2 as the PTV_70Gy size of 585cm^3^ was above the 90 percentile value of the model. This could have a negative effect on the predictions. RP2 parotid gland doses were 7 Gy higher than for AP for this case. Similarly, when applying RP1 to the patients in the group B, the Glottis was marked as outlier for each single patient, and the swallowing muscles received with RP1 in these patients the highest mean dose. This was also the organ in which the highest differences between RP1 and the other ATPs were observed, clearly showing that the model was not able to predict the correct objectives for this case. This could be overcome by deciding that patients with such warning signs by RapidPlan should not be subject to automated planning. In spite of this, we compared how RP1 and RP2 performed for each organ with the data from the own institution and the external patient data. We did not notice large dosimetric differences, demonstrating that rapidplan also works for patients with slightly different structure sets and prescriptions.

The time required to generate VMAT or IMRT plans has been reduced in the past years by improvement of the available tools in planning system as well as automation of steps in the optimization process time. Nowadays, planning templates, scripts and optimization automation are available in TPS. This allows a gain of time on one side and a standardization of the plan quality at a high level on the other side. The effective working time for ATPS planned with VMAT was reported to be less than 10 min with iCycle \[[@CR23]\] and less than 4 min with AP \[[@CR6]\], but the overall time was not recorded. The effective working time reported are in the same order as those from our study. By adding scripting to the automated optimization processes, effective planning time could be reduced to less than 2 min with RP and AIO. Similar scripting tools are also available in AP but were not implemented. This might have led to a similar reduction of the effective working time.

RS required substantially more time to generate VMAT plans as the other ATPS mainly for two reasons. The first reason is the shape of the target that needs to be convex in order to allow the algorithm to efficiently converge on an optimal solution \[[@CR17]\]. Earlier publications had shown that RS generated high quality plans in an efficient treatment planning time for convex target geometry \[[@CR6], [@CR18]\]. Therefore, each PTV geometry was approximated by a "more convex" or "less concave" geometry depending on the type of the nearest OAR (serial or parallel architecture). The second reason is that the HNC patients required a high-dimensional Pareto-surface approximation. Thus, the optimization time rises with the number of objective functions used during the optimization process. In our case, 20 objectives on average were used leading to a Pareto-surface approximation generated by 40 plans, as recommended by Craft et al. \[[@CR20]\] for each patient. The optimization time was similar for RP for both institutions. AIO, which is running on the same system as RP, needed a few minutes longer to finish the optimization since the optimization is paused to automatically adjust the objectives. AP performs multitude steps of optimization and dose calculation where the objectives and help structures are automatically adjusted and created. This iterative process is time consuming and lasts typically between 1 h and 1.5 h. The optimization time is increased to three to 4 h with RS due to the reasons mentioned above. However, this approach allows the user to select the plan having the best balance between the targets and OARS dose. The optimization time mentioned above can be influenced by the number of users working in parallel on the server as well as its performances; therefore this parameter should be taken only as a rough estimation of the optimization time.

This study was focused on HNC treatment and whether similar results will be obtained for other sites still needs to be assessed.

Conclusion {#Sec16}
==========

The results obtained for the five ATPS evaluated on two different set of HNC patients show that all ATPS were able to fulfill the hard constraints. For the parallel organs, AP achieved the best results followed by RS, AIO, RP2 and RP1. Nevertheless, the differences were small. The effective working time was reduced to less than 20′ for each ATPS, except RS, and could be reduced to less than 2′ when using scripting, which was the case for AIO and RP2.
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